The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Source: Roland Magnusson / Shutterstock.com LogicBio (NASDAQ: LOGC ) stock is seeing massive gains on Monday following news that AstraZeneca (NASDAQ: AZN ) subsidiary Alexion is acquiring the clinical...
LogicBio Therapeutics, Inc. (LOGC) announced it is being acquired in a deal valued at about $68 million. These are the details....
A stronger dollar is a boon for Consolidated Water (CWCO), Ashford Hospitality Trust (AHT), BankFinancial (BFIN), LogicBio Therapeutics (LOGC) and ProPhase Labs (PRPH) that have high domestic exposure...
Want to try an out-of-the-box approach? Tap Eastside Distilling (EAST), LogicBio Therapeutics (LOGC), Seabridge Gold (SA), Suzano (SUZ) and J Douglas Emmett (DEI)....
LogicBio Therapeutics Inc (NASDAQ: LOGC) shares are trading higher by 63.48% at $0.81 after the company announced the FDA lifted the clinical hold on its LB-001 Investigational New Drug Application, a...
Penny stocks to watch as stock market crash continues. The post Stock Market Crash: 4 Penny Stocks To Watch As Dow Slides appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStoc...
The FDA has lifted the clinical hold on LogicBio Therapeutics Inc's (NASDAQ: LOGC) LB-001 Investigational New Drug Application (IND) to resume patient enrollment in Phase 1/2 SUNRISE trial in pedi...
LEXINGTON, Mass. , March 23, 2022 /PRNewswire/ -- LogicBio ® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive office...
The FDA has placed a clinical hold on LogicBio Therapeutics Inc's (NASDAQ: LOGC) Phase 1/2 SUNRISE trial of LB-001 in pediatric patients with methylmalonic acidemia (MMA). The hold follows after t...